Abstract
We read with great interest the study of Takase et al1 on the addition of ezetimibe to lipid-lowering therapy (simvastatin) on coronary artery endothelial function. It shows that addition of ezetimibe not only lowers low-density lipoprotein cholesterol (Table 2) but also lowers important oxysterols (Table 3) and is associated with an improvement in coronary endothelial dysfunction. The main conclusions from the article (the presumed relation between a decrease in oxysterols and an improvement of coronary endothelial function), however, hinge on a post hoc analysis from the study. In Figure 5, the authors compare both treatment …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Arteriosclerosis, thrombosis, and vascular biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
